Navigation Links
Elsevier's Partners With QUOSA

AMSTERDAM, December 1 /PRNewswire-FirstCall/ --

- For Effective Literature Search and Document Management Workflow

EMBASE(R), Elsevier's biomedical and pharmaceutical abstract and indexing database, today announced that it has partnered with QUOSA(TM) to enable mutual customers to download and manage the full text of search results via a newly established channel in QUOSA Information Manager.

QUOSA Information Manager boosts journal retrieval, search and management efficiency for individual users through post-search automated full article retrieval, article organization and specialized full-text searching. It has proven an indispensable tool for extracting key information from full text quickly and more easily, for example, kinetic parameters, microarray data, adverse events and toxicity data. In combination with QUOSA Virtual Library, the partnership enables expert searches on to be integrated into an easy-to-use current awareness and literature access solution for larger groups.

Michael Rai, Director of Elsevier's Pharmaceutical Development Group, comments, "The partnership between and QUOSA opens up new possibilities and will no doubt help QUOSA users enhance their productivity and boost efficiency. It will now be much easier to navigate from the results of searches to the full text, which is seen as one important step to integrate critical information into a user's daily workflow." ( combines EMBASE and MEDLINE on one platform, providing users with timely and comprehensive access to pharmacological and biomedical literature. It contains records from over 7,000 journals published in more than 70 countries. Over 19 million bibliographic records are included with more than 2,000 new records added every working day. Users can navigate from citations to full text from the world's leading scientific, technical and medical (STM} publishers.

"The integration of as a channel for use with the QUOSA Information Manager and Virtual Library literature management application has been invaluable in our development of a Medical eLibrary Services group," according to Amyas Huston, Senior Manager Medical Communications, Cubist Pharmaceuticals, Inc. "The combined functionality allows our group to conduct searches against both the EMBASE and MEDLINE bibliographic databases, retrieve selected articles and provide a literature document repository for copyright-compliant web-based access of publications to internal colleagues."

Used extensively by the pharmaceutical industry, retrieves information to support such tasks as: new drug development and discovery of new applications for existing drugs, drug safety and pharmacovigilance procedures, legislative and regulatory compliance, clinical trial program management, PI/Supplementary Protection Certificates and IB writing and regulatory filing documentation such as New Drug Applications (NDAs).

"We are very pleased to have added to our supported channels, following on from our earlier support of Scopus," says Malcolm MacKenzie, President of QUOSA. " users can now benefit from the full power of our literature workflow solution, serving not only the information specialist's own needs, but also providing superior current awareness and literature management for project teams and the wider organization."

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (, MD Consult (, Scopus (, bibliographic databases and online reference works.

Elsevier ( is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


QUOSA Inc. is a specialist software company focused on supplying superior tools to life-science professionals for working with the scientific literature and research related documents. With a large and rapidly growing subscriber-base in academic and government research and medical centers and at leading pharmaceutical and biotechnology companies, QUOSA's applications are used to compress time to insight across the key functions of the research endeavour. For more information about QUOSA, please visit:

    Media Contact:
    Ann-Marie Roche

    EMBASE is a registered trademark of Elsevier BV.

SOURCE Elsevier
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):